Loading
Three cycles of gemcitabine and cisplatin before chemoradiotherapy cut recurrences and improved survival in locoregionally advanced nasopharyngeal cancer, making induction chemotherapy the standard in endemic regions.
Chinese multicentre randomised phase 3 trial of 480 patients with locoregionally advanced nasopharyngeal carcinoma (stage III to IVB, excluding T3-4N0 and T3N1) comparing three cycles of induction gemcitabine and cisplatin followed by concurrent cisplatin chemoradiotherapy with chemoradiotherapy alone.
Three-year recurrence-free survival was 85.3 percent with induction against 76.5 percent, and overall survival 94.6 percent against 90.3 percent, with the largest reduction in distant metastases; acute toxicity was higher during induction but late toxicity was similar.
Induction gemcitabine and cisplatin followed by chemoradiotherapy is the standard for locoregionally advanced nasopharyngeal carcinoma in endemic regions and in guidelines internationally.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Gemcitabine + cisplatin, Cisplatin.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.
Shares Gemcitabine + cisplatin, Cisplatin.